Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer

BACKGROUND: For stage II colorectal cancer (CRC), the efficacy of adjuvant chemotherapy remains controversial. Consensus molecular subtype (CMS) has been validated to be a prognostic tool for CRCs. In this study, CMS status was investigated as a prognostic biomarker for the efficacy of adjuvant chem...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Li, Yaqi, Yao, Qianlan, Zhang, Long, Mo, Shaobo, Cai, Sanjun, Huang, Dan, Peng, Junjie
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2020
Sujets:
Gastrointestinal Cancer
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8186407/
https://ncbi.nlm.nih.gov/pubmed/32926498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ONCO.13521
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires